According to business intelligence provider GBI (GlobalBusinessIntelligence) Research In 2013, The US treatment market for rheumatoid arthritis (RA) was $6.4 billion and which get rising to $9.3 billion by 2020, representing a Compound Annual Growth Rate (CAGR) of 5.5%. Resaon behind this sudden growth is US’ increasing prevalent population, which is reported to hit 1.68 million by 2020. Consequently, marketcurrently makes up the largest treatmentarea of the eight major pharmaceutical markets (the US, UK, Canada, France, Germany, Spain, Italy and Japan).